Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Gracell Biotechnologies Inc. Sponsored ADR (GRCL : NSDQ)
 
 • Company Description   
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company. It involved in discovering and developing breakthrough cell therapies to address unmet medical needs in the treatment of cancer. Gracell Biotechnologies Inc. is based in SUZHOU, China.

Number of Employees: 202

 
 • Price / Volume Information   
Yesterday's Closing Price: $6.84 Daily Weekly Monthly
20 Day Moving Average: 1,327,352 shares
Shares Outstanding: 67.50 (millions)
Market Capitalization: $461.69 (millions)
Beta:
52 Week High: $33.70
52 Week Low: $5.86
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -39.20% -37.30%
12 Week -47.26% -47.79%
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Building 12 Block B Phase II Biobay Industrial Park 218 Sangtian St.
-
Suzhou,F4 215123
CHN
ph: 86-512-6262-6701
fax: -
ir@gracellbio.com http://www.gracellbio.com
 
 • General Corporate Information   
Officers
William Wei Cao - Chief Executive Officer;Chairman and Founder
Yili Kevin Xie - Chief Financial Officer
Martina Sersch - Chief Medical Officer
David Guowei Wang - Director
Lili Shen - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 38406L103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 03/08/22
Share - Related Items
Shares Outstanding: 67.50
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $461.69 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.23 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.51
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 72.73%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/21 - -
06/30/21 - -
03/31/21 - -
ROA
09/30/21 - -
06/30/21 - -
03/31/21 - -
Current Ratio
09/30/21 - 14.70
06/30/21 - 16.05
03/31/21 - 18.38
Quick Ratio
09/30/21 - 14.70
06/30/21 - 16.05
03/31/21 - 18.38
Operating Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Net Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - 4.54
06/30/21 - 4.78
03/31/21 - 4.98
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.03
06/30/21 - 0.03
03/31/21 - 0.02
Debt-to-Capital
09/30/21 - 2.74
06/30/21 - 2.61
03/31/21 - 2.31
 

Powered by Zacks Investment Research ©